Piper Sandler Just Hiked Humana Price Target to $254: Medicare Advantage Beat Powers the Bull Case

"Humana stock received a price target raise to $254 from $182 from Piper Sandler, which maintained a Neutral rating. The move follows a Q1 2026 earnings beat driven by stronger Medicare Advantage performance and a favorable medical loss ratio (MLR). For prudent investors, the action signals that the longer-term margin recovery thesis is back in focus, even as Piper stays cautious on near-term execution."

"Piper's view that Humana has 560 basis points of Individual MA margin expansion available across 2027 and 2028, the central bull case in the call. The magnitude of the revision underscores Piper's conviction in the multi-year margin story. The roughly $72 price target raise ranks among the largest single-firm moves on Humana stock this cycle."

"Piper anchored its revised view on Humana's Q1 medical loss ratio beat and Medicare Advantage trends that were consistent with to slightly better than plan, in both new and tenured membership. The firm flagged that Humana is closely monitoring admissions, discharge, and transfer; pharmacy; authorization; and claims data, with April trend appearing stable as of April 29."

"The centerpiece of the upgrade is margin opportunity. Piper's 560 basis points of Individual MA margin expansion estimate across 2027 and 2028 matters because MLR is the dominant profit lever for any health insurer. The firm flagged that Humana is closely monitoring admissions, discharge, and transfer; pharmacy; authorization; and claims data, with April trend appearing stable as of April 29."

Humana received a raised price target to $254 from $182 while keeping a Neutral rating. The change followed a Q1 2026 earnings beat driven by stronger Medicare Advantage performance and a favorable medical loss ratio. The update refocused attention on a longer-term margin recovery thesis despite caution about near-term execution. The target increase reflects an estimated 560 basis points of Individual MA margin expansion available across 2027 and 2028, with medical loss ratio identified as the dominant profit lever for health insurers. The view is supported by Q1 medical loss ratio outperformance and Medicare Advantage trends that were consistent with or slightly better than plan across new and tenured membership, with April trends stable as of April 29.

Read at 24/7 Wall St.